Mayor Pro Tem Matsumoto Joins Pump It Up For Platelets Awareness Walk

South San Francisco, CA    September 19, 2018

Last Thursday,  September 13, Rigel Pharmaceuticals hosted South San Francisco Mayor Pro Tem Karyl Matsumoto at a ceremony that proclaimed September to be “ITP Awareness Month.” Following the proclamation presentation, Mayor Pro Tem Matsumoto joined nearly all Rigel employees on a “Pump it Up for Platelets” Awareness Walk along the South San Francisco Bay Trail to raise money for and awareness of chronic immune thrombocytopenia. Rigel organized the walk in partnership with the Platelet Disorder Society of America to support its month-long disease awareness campaign.

Presentation of Proclamation of ITP Awareness Month with Mayor Pro Tem Karyl Matsumoto and Rigel president and CEO Raul Rodriguez


“It was a really great event and the work Rigel is doing is phenomenal.” said Mayor Pro Tem Matsumoto “It makes me so proud that SSF is providing a place where biotech and life science companies have an environment in which to share and exchange ideas and the bottom line is that people benefit from their endeavors.”


Rigel employees Pump It Up For Platelets


About Chronic ITP:

In patients with ITP, the immune system attacks and destroys the body’s own blood platelets, which play an active role in blood clotting and healing.  Common symptoms of ITP are excessive bruising and bleeding.  People suffering with chronic ITP may live with an increased risk of severe bleeding events that can result in serious medical complications or even death.  Current therapies for ITP include steroids, blood platelet production boosters (TPOs) and splenectomy. However, not all patients are adequately treated with existing therapies. As a result, there remains a significant medical need for additional treatment options for patients with ITP.

Just this past April, Rigel received FDA approval of its first product, a treatment for chronic immune thrombocytopenia (ITP).

For more information about Rigel:

For more information about TAVALISSE, a new treatment for ITP (and the company’s first ever FDA approved product), visit

For more information on PDSA:


0 0 votes
Article Rating
Notify of

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Inline Feedbacks
View all comments